Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H44O12 |
Molecular Weight | 584.6525 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O
InChI
InChIKey=LPMXVESGRSUGHW-HBYQJFLCSA-N
InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
Molecular Formula | C29H44O12 |
Molecular Weight | 584.6525 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB01092Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23761677
http://www.druginfosys.com/drug.aspx?drugcode=537&type=9
Sources: https://www.drugbank.ca/drugs/DB01092
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23761677
http://www.druginfosys.com/drug.aspx?drugcode=537&type=9
There is no available information about this compound
Originator
Sources: http://www.jbc.org/content/96/3/647.full.pdf
Curator's Comment: Ouabain was discovered and so named in 1888 by Amaud
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P50993 Gene ID: 477.0 Gene Symbol: ATP1A2 Target Organism: Homo sapiens (Human) Sources: http://www.selleckchem.com/products/ouabain.html |
41.0 nM [Ki] | ||
Target ID: P13637 Gene ID: 478.0 Gene Symbol: ATP1A3 Target Organism: Homo sapiens (Human) Sources: http://www.selleckchem.com/products/ouabain.html |
15.0 nM [Ki] | ||
Target ID: CHEMBL390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23621895 |
63.0 nM [IC50] | ||
Target ID: CHEMBL392 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23621895 |
37.0 nM [IC50] | ||
Target ID: P05023|||Q9UJ20 Gene ID: 476.0 Gene Symbol: ATP1A1 Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB01092 |
50.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Ouabain Approved UseOuabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias. |
|||
Primary | Ouabain Approved UseOuabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias. |
|||
Primary | Ouabain Approved UseOuabain is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Left ventricular failure, Ventricular arrhythmias. |
|||
PubMed
Title | Date | PubMed |
---|---|---|
Ouabain-induced ventricular tachycardia and its effect on the performance and metabolism of the dog heart. | 1959 Sep |
|
The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. | 1968 Sep |
|
Antiarrhythmic and antifibrillatory properties of aprindine. | 1975 Aug |
|
[Inhibitory effect of taurine on ouabain-induced arrythmia]. | 1975 Jan |
|
The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs. | 1975 Jan-Feb |
|
[Glycogen content in rat brain in ouabain encephalopathy]. | 1975 Jan-Mar |
|
[Pharmacological studies of celiprolol: III. Effects of celiprolol on the cardiovascular system and renal function, and its antiarrhythmic effects]. | 1990 Apr |
|
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991 Jan-Feb |
|
Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. | 1992 |
|
Neuronal Fos-like immunoreactivity in ouabain-induced hypertension. | 2000 Sep 8 |
|
Activation of Na+/K+-ATPase by the serum and glucocorticoid-dependent kinase isoforms. | 2002 |
|
The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. | 2004 Aug |
|
Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain. | 2004 Nov |
|
[Renal sodium handling in ouabain-hypertensive rats]. | 2005 Aug |
|
The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. | 2005 Feb |
|
[Comparative study of properties of Na+, K+-ATPase and Mg2+-ATPase of the myometrium plasma membrane]. | 2005 Mar-Apr |
|
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats. | 2008 Aug |
|
Ouabain treatment changes the role of endothelial factors in rat resistance arteries. | 2008 Dec 14 |
|
ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit. | 2008 Jul |
|
Chronic ouabain treatment increases the contribution of nitric oxide to endothelium-dependent relaxation. | 2008 Jun |
|
Structural and functional characteristic of a model for deep-seated lacunar infarct in rats. | 2008 Oct 15 |
|
Response of sodium pump to ouabain challenge in human glioblastoma cells in culture. | 2009 |
|
Chronic ouabain treatment induces vasa recta endothelial dysfunction in the rat. | 2009 Jan |
|
Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. | 2009 Nov 1 |
|
The new targets of ouabain in retinal interneurons of Sprague-Dawley rats. | 2010 Apr 5 |
|
Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain. | 2010 Feb |
|
DNA damage after intracerebroventricular injection of ouabain in rats. | 2010 Feb 26 |
|
Upregulation of Na+ and Ca2+ transporters in arterial smooth muscle from ouabain-induced hypertensive rats. | 2010 Jan |
|
Effects of long-term ouabain treatment on blood pressure, sodium excretion, and renal dopamine D(1) receptor levels in rats. | 2010 Jan |
|
Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes. | 2010 Jan 1 |
|
Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. | 2010 Jul 1 |
|
Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. | 2010 Jun |
|
Dopamine-mediated inhibition of renal Na+/K+-ATPase in HK-2 cells is reduced by ouabain. | 2010 May |
Patents
Sample Use Guides
0.004 mg/kg - IV, as Recommended Initial dose
24 mg 24 hourly PO, as Maintenance dose
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.selleckchem.com/products/ouabain.html
Ouabain (0.1 uM-1.0 uM) inhibits the Na+ pump and increases stored Ca2+ in cultured rat astrocytes.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:16 GMT 2025
by
admin
on
Mon Mar 31 18:21:16 GMT 2025
|
Record UNII |
5ACL011P69
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C01AC01
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
||
|
WHO-VATC |
QC01AC01
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D010042
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
472805
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
211-139-3
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
100000076204
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
5ACL011P69
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
3519
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL222863
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
439501
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
2004
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
4826
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
SUB14721MIG
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
7762
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
OUABAIN
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
DB01092
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
m8270
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
145798
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
25485
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
DTXSID0043765
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
630-60-4
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | |||
|
m10252
Created by
admin on Mon Mar 31 18:21:16 GMT 2025 , Edited by admin on Mon Mar 31 18:21:16 GMT 2025
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SOLVATE->ANHYDROUS | |||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |